Biological activity and clinical implications of the matrix metalloproteinases

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1389-1397

  Rydlova, M ^a   Holubec Jr , Lubos ^b   Ludvikova Jr , M ^b   Kalfert, D ^c   Franekova, J ^d   Povysil, C ^f   Ludvikova, M ^e,f  

^a UNIVERSITY OF OSTRAVA   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer; Matrix metalloproteinases; Review; Thyroid neoplasm

Indexed keywords

MATRIX METALLOPROTEINASE; TUMOR MARKER;

BIOLOGICAL ACTIVITY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER THERAPY; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; HUMAN; METASTASIS; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; THYROID CANCER;

HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEASE INHIBITORS; THYROID NEOPLASMS;

EID: 42549163274     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Curran S and Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
2. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O and Resnick MB: Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr Med Assoc J 4: 247-251, 2002.
3. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241, 1999.
4. Massi D, Franchi A, Ketabchi S, Paglierani M, Pimpinelli N and Santucci M: Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol 34: 80-88, 2003.
5. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
6. Mannello F: Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon? Recent Patents on Anti-Cancer Drug Discovery 1: 91-103, 2006.
7. Krüger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S and Fridman R: Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65: 3523-3526, 2005.
8. Rudek MA, Venitz J and Figg WD: Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22: 705-720, 2002.
9. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899-909, 2004.
10. Parks WC and Mecham RP (eds.): Matrix Metalloproteinases. San Diego, Academic Press, 1998.
11. Nagel H, Laskawi R, Wahlers A and Hemmerlein B: Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 44: 222-231, 2004.
12. Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skrickova J, Sheehan CE and Ross JS: Expression of matrix metalloproteinase 3,10,11 (stromelysins 1,2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Ces-slov Patol 42: 6-19, 2006 (in Czech).
13. Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S, Mukai K and Monden Y: Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metallopro-teinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 98: 1822-1829, 2003.
14. Kumamoto H, Yamauchi K, Yoshida M and Ooya K: Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 32: 114-120, 2003.
15. Mitani O, Katoh M and Shigematsu H: Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis. Pathol Int 54: 241-250, 2004.
16. Span PN, Sweep CG, Manders P, Beex LV, Leppert D and Lindberg RL: Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97: 2710-2715, 2003.
17. Holubec L sen, Holubec L Jr, Ludvikova M, Topolcan O, Treska L and Finek J: Colorectal Carcinoma. Praha, Grada Publishing, 2004 (in Czech).
18. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y and Hamaguchi M: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 48: 286-294, 2006.
19. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 52: 255-264, 2002.
20. Woessner FJ and Nagase H (eds): Matrix Metalloproteinases and TIMPs. Oxford University Press, Oxford, 2000.
21. Xu Z, Zhao S, Zhou H, Ye H and Li J: Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem 50: 750-753, 2004.
22. Takahashi E, Tateyama H, Akatsu H, Fukai I, Yamakawa Y, Fujii Y and Eimoto T: Expresssion of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organisation classification subtype and clinical stage of thymic epithelial tumors. Hum Pathol 34: 1253-1258, 2003.
23. Gonzxles AA, Segura AM, Horiba K, Qian S, Yu ZX, Stetler-Stevenson W, Willerson JT, McAllister HA Jr and Ferrans VJ: Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study. Hum Pathol 33: 1158-1164, 2002.
24. Butera J, Malachovsky M, Rathore R and Safran H: Novel approaches in development for the treatment of pancreatic cancer. Fronts in Biosci 3: E 226-229, 1998.
25. D'Armiento J: Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 12: 97-101, 2002.
26. Overall CM: Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J 383: e5-7, 2004.
27. Shah PK and Galis ZS: Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 104: 1878-1880, 2001.
28. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR and Loftus IM: Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110: 337-343, 2004.
29. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
30. Arribas A: Matrix metalloproteases and tumor invasion. NEJM 352: 2020-2021, 2005.
31. Nguyen N, Kuliopulos A, Graham RA and Covic L: Tumor-derived Cyr61 (CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 66: 2658-2665, 2006.
32. Dunbar SA: Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 363: 71-82, 2006.
33. Bird NC, Mangnall D and Majeed AW: Biology of colorectal liver metastases: a review. J Surg Oncol 94: 68-80, 2006.
34. Beard SM, Holmes M, Price C and Majeed AW: Hepatic resection for colorectal liver metastases: a cost effective analysis. Ann Surg 232: 763-776, 2000.
35. Baker EA, Bergin FG and Leaper DJ: Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87: 1215-1221, 2000.
36. Tomita T and Iwata K: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomasadenokarcinomas. Dis Colon Rectum 39: 1255-1264, 1996.
37. Theret N, Musso O, Campion JP, Turlin B, Loreal O, LÏHelgoualcÏ h A and Clement B: Overexpression of matrix-metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastases. Int J Cancer 74: 426-432, 1997.
38. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J and Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25: 3387-3391, 2005.
39. Adachi Y, Yamamoto H and Itoh F: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal-cancers. Gut 45: 252-258, 1999.
40. Ichikawa Y, Ishikawa T, Momiyama N, Yamaguchi S, Masui H, Hasegawa S, Chishima T, Takimoto A, Kitamura H, Akitaya T, Hosokawa T, Mitsuhashi M and Shimeda H: Detection of regional lymph node metastases in colon cancer by using RT- PCR for matrix metalloproteinase 7, matrilysin. Clin Exp Metast 16: 3-8, 1998.
41. Matsuyama Y, Sohshin T and Takashi A: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. Surg Oncology 80: 105-110, 2002.
42. Gomez DE, Alonso DF, Yoshiji H and Thorgeisson UP: Tissue inhibitors of metalloproteinasses: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997.
43. Tien YW, Lee PH, Hu RH, Hsu SM and Chang KJ: The role of gelatinase in hepatic metastatis of colorectal cancer. Clinical Cancer Research 9: 4891-4896, 2003.
44. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB and Urist MM: Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surgery 233: 786-792, 2001.
45. Waas ET, Wobbes T, Ruers T, Lomme RM and Hendriks T: Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol 32: 756-763, 2006.
46. Ishida H, Murata N, Tada M, Okada N, Hashimoto D, Kubota S, Shirakawa K and Wakasugi H: Determining the levels of matrix metalloproteinases-9 in portal and peripheral blood is useful for predicting liver metastases of colorectal cancer. Jpn J Clin Oncol 33: 186-191, 2003.
47. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10: 8229-8234. 2004.
48. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE and Turner DR: Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 49: 666-672, 1991.
49. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W and Guillem JG: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906, 1995.
50. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K and Kobayashi M: Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 26: 303-309, 1996.
51. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W and Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299, 2000.
52. Pesta M, Topolcan O, Holubec L Jr, Rupert K, Cerna M, Holubec LS, Treska V, Finek J and Cerny R: Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 27: 1863-1868, 2007.
53. Pikner R, Ludvikova M, Ryska A, Kholova I, Holubec L Jr, Topolcan O, Pecen L and Fínek J: TPS, thymidine kinase, VEGF and endostatin in cytosol of thyroid tissue samples. Anticancer Res 25: 1517-1522, 2005.
54. Kholová I, Ludviková M, Ryska A, Topolcan O, Pikner R, Pecen L, Cap J and Holubec L Jr: Diagnostic role of markers dipeptidyl peptidase IV and thyroid peroxidase in thyroid tumors. Anticancer Res 23: 871-876, 2003.
55. Ludvikovx M, Holubec L Jr, Ryska A and Topolcan O: Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-α immunostaining. Anticancer Res 25: 1835-1840, 2005.
56. Kholová I, Ludviková M, Ryska A and Cap J: Dipeptidyl(amino)peptidase IV in the differential diagnosis of thyroid gland tumors: methods and results of a pilot study of 200 cases. Cesk Patol 38: 11-17, 2002 (in Czech).
57. Laco J and Ryska A: The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern. Cesk Patol 42: 120-124, 2006 (in Czech).
58. Maeta H, Ohgi S and Terada T: Protein expression of matrix metallloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438: 121-128, 2001.
59. Patel A, Straight AM, Mann H, Duffy E, Fenton C, Dinauer C, Tuttle RM and Francis GL: Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 25: 403-408, 2002.
60. Campo E, Merino MJ, Liotta L, Neumann R and Stetler-Stevenson W: Distribution of the 72-kDa type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23: 1395-1401, 1992.
61. Pasieka Z, Stepien H, Czyz W, Pomorski L and Kuzdak K: Concentration of MMP-2 and TIMP-2 in the serum of patients with benign and malignant thyroid tumours treated surgically. Endocr Regul 38: 57-63, 2004.